Download biomedica product list
Sclerostin is associated with risk for arterial stiffness
Arterial stiffness (AS) is characterized by stiffening of the vascular wall, which diminishes its ability to expand and contract in response to blood flow. It is a natural aspect of aging, driven by structural and cellular alterations in the vessel walls, and tends to accelerate in the presence of cardiovascular risk factors like diabetes, hypertension, and others (1). The development of AS involves dysregulation of elastin fibers and collagen, oxidative stress, disrupted mineral metabolism, and low-grade inflammation. Multiple factors contribute to its progression, including oxidative stress, inflammation, vascular calcification, and the combined effects of traditional cardiovascular risk factors such as diabetes mellitus and hypertension (2). Arterial stiffness can lead to increased myocardial preload and decreased perfusion pressure in the coronary arteries. Importantly, AS is a predictor of future cardiovascular disease (CVD), as heightened arterial stiffness can cause higher systolic blood pressure, increased cardiac workload, and a greater likelihood of events like heart attack and stroke (3).
Sclerostin is associated with risk for arterial stiffness
Sclerostin is primarily known for its role in controlling bone formation, but it is also expressed in the heart, aorta, and arteries (4). A recent study in community dwelling women revealed that lower serum sclerostin levels were associated with elevated risks for increased AS (5).
Sclerostin levels were measured with the
Biomedica SCLEROSTIN ELISA Assay | BI-20492
- most referenced in over 300 publications
- full validation package
- for serum and plasma – sample volume: 20µl / well
Example of a typical ELISA assay with color coded, ready to use reagents
Literature:
- Arterial Stiffness in Aging: Does It Have a Place in Clinical Practice?: Recent Advances in Hypertension. Mitchell GF. Hypertension. 2021 Mar 3;77(3):768-780. doi: 10.1161/HYPERTENSIONAHA.120.14515. Epub 2021 Feb 1. PMID: 33517682..
- Hypertension, Arterial Stiffness, and Diabetes: a Prospective Cohort Study. Tian X, Zuo Y, Chen S, Zhang Y, Zhang X, Xu Q, Wu S, Wang A. Hypertension. 2022 Jul;79(7):1487-1496. doi: 10.1161/HYPERTENSIONAHA.122.19256. Epub 2022 May 16. PMID: 35574838; PMCID: PMC9172905.
- Role of arterial stiffness in cardiovascular disease. Cecelja M, Chowienczyk P. JRSM Cardiovasc Dis. 2012 Jul 31;1(4):cvd.2012.012016. doi: 10.1258/cvd.2012.012016. PMID: 24175067; PMCID: PMC3738327.
- Role of Sclerostin in Cardiovascular Disease. Golledge J, Thanigaimani S. Arterioscler Thromb Vasc Biol. 2022 Jul;42(7):e187-e202. doi: 10.1161/ATVBAHA.122.317635. Epub 2022 May 12. PMID: 35546488.
- Association of Lower Serum Sclerostin Levels With Elevated Risk for Increased Arterial Stiffness: The JPOS Cohort Study. Tamaki J, Tachiki T, Jaalkhorol M, Dongmei N, Komastu M, Tsuda K, Kudo A, Kamiya K, Kouda K, Kajita E, Kagamimori S, Iki M. J Clin Endocrinol Metab. 2025 Jul 15;110(8):2225-2235. doi: 10.1210/clinem/dgae795. PMID: 39530177.